TheraRadar
← Back
Data updated: May 24, 2026

NAVINTA LLC

Generics

NAVINTA LLC is a generic drug manufacturer focused on Immunology, Infectious Disease, Neurology. Key products include SODIUM PHENYLACETATE AND SODIUM BENZOATE.

2008
Since
22
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Immunology 29%
2 drugs
Infectious Disease 29%
2 drugs
Neurology 14%
1 drugs
Cardiovascular 14%
1 drugs
Oncology 14%
1 drugs

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • SODIUM PHENYLACETATE AND SODIUM BENZOATE leads revenue
  • Drug-level revenue analysis

Trial Catalysts

  • Immunology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling